Sarepta Therapeutics (SRPT) Numbers Raised at BofA Securities After Predicting Profitability in 2024
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $105.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
